Pipeline — registered trials by phase
Mast Cell Connect: A Registry for Patients With Mastocytosis
— · Mastocytosis · Completed · est. 2021-01
(PROSPECTOR) Screening Study Evaluating the Prevalence of the KIT D816V Mutation in Patients With Systemic Mast Cell Activation
— · Systemic Mast Cell Activation, KIT D816V Mutation · Completed · est. 2023-03-31
Avapritinib Rollover Study
— · Mastocytosis, Systemic · Recruiting · est. 2027-12-31
Screening Study for KIT D816V Mutated Mast Cell Disease in Select Populations
— · Clonal Mast Cell Disease, KIT D816V Mutation, Suspected KITD816V Mutated Clonal Mast Cell Disease · Recruiting · est. 2028-07-31
An Observational Study in Participants With Indolent Systemic Mastocytosis (ISM)
— · Indolent Systemic Mastocytosis · Recruiting · est. 2032-12-01
Retrospective Study Assessing the Effect of Avapritinib Versus Best Available Therapy in Patients With AdvSM
— · Advanced Systemic Mastocytosis, Aggressive Systemic Mastocytosis, Systemic Mastocytosis With an Associated Hematological Neoplasm · Completed · est. 2021-10-04
A Non-Interventional Study in Participants With Indolent Systemic Mastocytosis (ISM) in Germany
— · Indolent Systemic Mastocytosis · Recruiting · est. 2028-12-01
Study for Patients Previously Treated in Avapritinib Clinical Trials
— · Gastrointestinal Stromal Tumors · Completed · est. 2023-11-23
A Phase 1 Study of Fisogatinib (BLU-554) in Patients With Hepatocellular Carcinoma
— · Hepatocellular Carcinoma (HCC) · Completed · est. 2021-06-30
(NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors
— · Gastrointestinal Stromal Tumors (GIST), Other Relapsed or Refractory Solid Tumors · Completed · est. 2020-03-06
Safety, Tolerability, Pharmacokinetics, and Food Effect of BLU-782 in Healthy Adults
— · Healthy Volunteers · Completed · est. 2019-09-11
Study of BLU-808 in Healthy Adult Participants
— · Healthy Participants · Completed · est. 2025-01-21
(EXPLORER) Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory Myeloid Malignancies
— · Aggressive Systemic Mastocytosis, Systemic Mastocytosis-associated Hematologic Non-mast Cell Disease, Mast Cell Leukemia · Completed · est. 2022-10-05
A Study of Elenestinib in Healthy Adult Female Participants
— · Healthy Participants · Completed · est. 2026-04-02
A Drug-drug Interaction Study of Avapritinib and Midazolam
— · Gastrointestinal Stromal Tumors, GIST, Non-resectable Advanced Solid Tumors · Completed · est. 2024-03-01
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
— · Advanced Solid Tumor, Non-Small Cell Lung Cancer, Colorectal Neoplasms · Recruiting · est. 2029-09
Study of BLU-808 in Allergic Rhinoconjunctivitis
— · Allergic Rhinoconjunctivitis · Completed · est. 2025-09-08
(PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis
— · Advanced Systemic Mastocytosis, Aggressive Systemic Mastocytosis, Systemic Mastocytosis With an Associated Hematologic Neoplasm · Completed · est. 2024-12-18
(PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic Mastocytosis
— · Indolent Systemic Mastocytosis · Active Not Recruiting · est. 2027-06-23
A Study of Avapritinib in Pediatric Patients With Solid Tumors Dependent on KIT or PDGFRA Signaling
— · Solid Tumor, Unspecified, Child, Relapsed Solid Neoplasm, CNS Tumor · Completed · est. 2025-11-21
Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU)
— · Chronic Inducible Urticaria, Chronic Spontaneous Urticaria · Active Not Recruiting · est. 2026-12-31
(VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST
— · GIST · Completed · est. 2020-03-09
(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis
— · Indolent Systemic Mastocytosis, Smoldering Systemic Mastocytosis · Recruiting · est. 2032-09-30
AyvakitAvapritinib
GavretoPralsetinib
Source: ClinicalTrials.gov (trials where Blueprint Medicines is lead sponsor; 23 active or completed) and Drugs@FDA (2 approved products). Registry data can include older or partnered programs; the company's own pipeline page is the official list.
SEC filings — insider trading forms excluded
- No filings found.
Source: SEC EDGAR. Forms 3/4/5 and 144 (insider transactions) are intentionally left out.